Wang Zhangyan, Hong Huangming
Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China.
Mol Clin Oncol. 2025 Mar 26;22(5):45. doi: 10.3892/mco.2025.2840. eCollection 2025 May.
Compared with other metastatic sites, breast cancer brain metastases (BCBMs) are associated with the shortest survival time. In addition, human epidermal growth factor receptor 2 (HER2) is observed to be amplified in 20-25% of breast cancer cases where it is a poor prognostic factor for brain metastases. Various anti-HER2 targeted therapies have brought both new opportunities and challenges to patients with HER2-positive BCBM over the past decade. However, prolonging survival time and improving quality of life of patients have become controversial issues in the field of clinical research on BCBMs. On the basis of the latest literature, the present review documents the anti-HER2 targeted drugs applied in patients with HER2-positive BCBM. Further studies on the efficacy and safety of novel HER2-targeted drugs and combined or sequential therapy in clinical treatment are expected to provide more effective strategies for the treatment of patients with HER2-positive BCBM.
与其他转移部位相比，乳腺癌脑转移（BCBM）的生存时间最短。此外，在20%-25%的乳腺癌病例中观察到人类表皮生长因子受体2（HER2）扩增，这是脑转移的不良预后因素。在过去十年中，各种抗HER2靶向治疗给HER2阳性BCBM患者带来了新的机遇和挑战。然而，延长患者生存时间和提高生活质量已成为BCBM临床研究领域中存在争议的问题。基于最新文献，本综述记录了应用于HER2阳性BCBM患者的抗HER2靶向药物。对新型HER2靶向药物在临床治疗中的疗效和安全性以及联合或序贯治疗的进一步研究，有望为HER2阳性BCBM患者的治疗提供更有效的策略。
